Sienna Cancer Diagnostics Limited, a medical technology company, identifies, develops, and commercializes cancer-related in-vitro diagnostic tests for use in pathology laboratories worldwide.
The last earnings update was 88 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Sienna Cancer Diagnostics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
Sienna Cancer Diagnostics's
is considered below, and whether this is a fair price.
Price based on past earnings
Sienna Cancer Diagnostics's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sienna Cancer Diagnostics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Sienna Cancer Diagnostics
expected to grow at an
Unable to compare Sienna Cancer Diagnostics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Sienna Cancer Diagnostics's earnings growth to the Australia market average as no estimate data is available.
Unable to compare Sienna Cancer Diagnostics's revenue growth to the Australia market average as no estimate data is available.
Unable to determine if Sienna Cancer Diagnostics is high growth as no earnings estimate data is available.
Unable to determine if Sienna Cancer Diagnostics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Sienna Cancer Diagnostics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
Sienna Cancer Diagnostics
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Sienna Cancer Diagnostics's finances.
The net worth of a company is the difference between its assets and liabilities.
Sienna Cancer Diagnostics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Sienna Cancer Diagnostics's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Sienna Cancer Diagnostics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Sienna Cancer Diagnostics has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Carl S. Stubbings, BSc serves as Chief Executive Officer and Managing Director of Sienna Cancer Diagnostics Limited since October 16, 2019. Mr. Stubbings served as Chief Executive Officer at BCAL Diagnostics Pty Ltd. since 2019. Mr. Stubbings served as the Head of Commercialisation at BCAL Diagnostics Pty Ltd. since October 24, 2016 until 2019. He served as Acting Chief Executive Officer of Sienna Cancer Diagnostics Limited from August 2016 to March 2017. He has been Director of Sienna Cancer Diagnostics Limited since December 31, 2011. He serves as an Independent Non-Executive Director at Biomics Biopharma Limited. He serves as a Non-Executive Director of Sienna Diagnostics, providing strategic direction for its high performing cancer diagnostic test. He serves as a Director of Sienna Cancer Diagnostics Unlisted Public Company and Otakaro Pathways New Zealand based Private Company. He serves as a Director of Analytica Medical. He served as Non-Executive Director of Analytica Ltd. from January 13, 2014 to November 30, 2017. He served as the Chief Business Officer of Benitec Biopharma Limited from July 2, 2012 to July 31, 2016, where he focused on developing and executing the commercialisation strategy including licensing and partnership agreements. Mr. Stubbings served as a Vice President of Sales & Marketing at Diasorin Molecular LLC (formerly, Focus Diagnostics, Inc.). Mr. Stubbings joined Focus in 2007. He served as Vice President of Business Development for Panbio Inc. at Inverness Medical Innovations Australia Pty Limited and headed up Panbio Inc. USA. He served as Senior Vice President of Panbio Inc. and served as its Vice President of Business Development since November 6, 2006. He has more than 30 years’ experience in sales and marketing in the health care industry with specific experience in diagnostics, nuclear medicine, life sciences and private pathology. He has specialised in sales with a particular emphasis on marketing across North America, Latin America, Asia Pacific and Europe as well as roles covering manufacturing and administration. He is active member of the Queensland Government’s North American Biotechnology Advisory Council and a member of the American Society of Tropical Medicine and Hygiene. He earned a B.Sc. from Queensland University of Technology, Brisbane, Australia.
Carl's compensation has increased whilst company is loss making.
Carl's remuneration is lower than average for companies of similar size in Australia.
CEO, MD & Director
Tony Di Pietro
CFO & Company Secretary
Board of Directors Tenure
Average tenure of the
Sienna Cancer Diagnostics
board of directors in years:
The tenure for the Sienna Cancer Diagnostics board of directors is about average.
Board of Directors
Independent Non-Executive Chairman
CEO, MD & Director
Independent Non-Executive Director
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Volatility 101: Should Sienna Cancer Diagnostics (ASX:SDX) Shares Have Dropped 33%?
Investors in Sienna Cancer Diagnostics Limited (ASX:SDX) have tasted that bitter downside in the last year, as the share price dropped 33%. … We've already covered Sienna Cancer Diagnostics's share price action, but we should also mention its total shareholder return (TSR). … We note that Sienna Cancer Diagnostics's TSR, at -30% is higher than its share price return of -33%.
Can We See Significant Insider Ownership On The Sienna Cancer Diagnostics Limited (ASX:SDX) Share Register?
As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.' Sienna Cancer Diagnostics is a smaller company with a market capitalization of AU$17m, so it may still be flying under the radar of many institutional investors. … View our latest analysis for Sienna Cancer Diagnostics ASX:SDX Ownership Summary, May 15th 2019 What Does The Institutional Ownership Tell Us About Sienna Cancer Diagnostics? … Insider Ownership Of Sienna Cancer Diagnostics While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders.
Did Sienna Cancer Diagnostics Limited (ASX:SDX) Insiders Buy Up More Shares?
So shareholders might well want to know whether insiders have been buying or selling shares in Sienna Cancer Diagnostics Limited (ASX:SDX). … But logic dictates you should pay some attention to whether insiders are buying or selling shares. … The Last 12 Months Of Insider Transactions At Sienna Cancer Diagnostics.
Could The Sienna Cancer Diagnostics Limited (ASX:SDX) Ownership Structure Tell Us Something Useful?
Every investor in Sienna Cancer Diagnostics Limited (ASX:SDX) should be aware of the most powerful shareholder groups. … With a market capitalization of AU$17m, Sienna Cancer Diagnostics is a small cap stock, so it might not be well known by many institutional investors. … See our latest analysis for Sienna Cancer Diagnostics
What does Sienna Cancer Diagnostics Limited's (ASX:SDX) Balance Sheet Tell Us About Its Future?
The direct benefit for Sienna Cancer Diagnostics Limited (ASX:SDX), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … Is SDX growing fast enough to value financial flexibility over lower cost of capital. … Debt capital generally has lower cost of capital compared to equity funding
How Financially Strong Is Sienna Cancer Diagnostics Limited (ASX:SDX)?
The direct benefit for Sienna Cancer Diagnostics Limited (ASX:SDX), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … Does SDX's growth rate justify its decision for financial flexibility over lower cost of capital … Debt capital generally has lower cost of capital compared to equity funding.
Sienna Cancer Diagnostics Limited, a medical technology company, identifies, develops, and commercializes cancer-related in-vitro diagnostic tests for use in pathology laboratories worldwide. The company offers SCD-A7, an anti-human telomerase reverse transcriptase antibody for the detection of the biomarker for cancer. It also provides SIEN-NET technology, a sample preparation platform to enhance the performance of liquid biopsy diagnostic assays. The company has a research collaboration agreement with Minomic International Ltd to develop a proprietary test for the early detection of pancreatic cancer. The company was formerly known as Sienna Capital Ltd and changed its name to Sienna Cancer Diagnostics Limited in 2006. Sienna Cancer Diagnostics Limited was founded in 2002 and is headquartered in Scoresby, Australia.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.